Levomilnacipran Extended-Release Capsules Suppliers & Bulk Manufacturers

Available Forms: Extended-Release Capsules

Available Strengths: 20 mg, 40 mg, 80 mg, 120 mg

Reference Brands: Fetzima®(US)

Category: Antipsychotropic Drugs

Levomilnacipran Extended-Release Capsules is available in Extended-Release Capsules and strengths such as 20 mg, 40 mg, 80 mg, 120 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Levomilnacipran Extended-Release Capsules is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Levomilnacipran Extended-Release Capsules can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description: Levomilnacipran extended-release (ER) capsules are FDA-approved in the United States for the treatment of major depressive disorder (MDD) in adults. As a serotonin-norepinephrine reuptake inhibitor (SNRI), the ER formulation provides consistent plasma levels and once-daily dosing. U.S. regulations mandate boxed warnings for increased suicidal thoughts in young adults, GMP-compliant manufacturing, bioequivalence studies for generics, and post-marketing pharmacovigilance. In the European Union, levomilnacipran is not widely marketed, but companies may pursue national or decentralized procedures for approval. EU requirements include a comprehensive Risk Management Plan (RMP), clinical safety and efficacy data, and robust pharmacovigilance measures. For dossier-ready sourcing, visit Pharmatradz.com.